[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Barry Moze Biography and Net Worth

EVP of Horizon Therapeutics Public

Barry J. Moze joined Horizon in June 2014 and in his current role is responsible for all business operations and project management, including information technology. Before joining Horizon, he spent more than 25 years as partner and owner of Crystal Clear Communications, a consulting firm focused on working with board of directors, chief executive officers and executive teams to develop and execute their corporate strategies. In addition, Moze assisted building organizational behaviors and competencies needed to drive effective organizations. Moze has worked with Fortune 500 and 1000 companies such as Abbott, Pepsi Bottling Group, W.W. Grainger, Genentech, Rockwell Automation and Manpower.

Before Crystal Clear, Moze was a founder and president of Review Services and Asset Management Group, a licensed investment advisory firm. He serves on the board of Palermo Villa, a private company.

What is Barry Moze's net worth?: The estimated net worth of Barry Moze is at least $13.96 million as of April 12th, 2021. Mr. Moze owns 120,025 shares of Horizon Therapeutics Public stock worth more than $13,958,908 as of November 15th. This net worth approximation does not reflect any other investments that Mr. Moze may own. Learn More about Barry Moze's net worth.
How do I contact Barry Moze?: The corporate mailing address for Mr. Moze and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Barry Moze's contact information.
Has Barry Moze been buying or selling shares of Horizon Therapeutics Public?: Barry Moze has not been actively trading shares of Horizon Therapeutics Public during the last ninety days. Most recently, Barry Moze sold 35,076 shares of the business's stock in a transaction on Thursday, July 8th. The shares were sold at an average price of $92.54, for a transaction totalling $3,245,933.04. Learn More on Barry Moze's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Barry Moze Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/8/2021	Sell	35,076	$92.54	$3,245,933.04
4/12/2021	Sell	65,613	$88.96	$5,836,932.48	120,025
7/1/2020	Sell	23,158	$54.64	$1,265,353.12	145,242
3/30/2020	Sell	2,106	$28.18	$59,347.08	168,397

Barry Moze Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03